Globeflex Capital L P Has $154,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Globeflex Capital L P lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 15.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 965 shares of the specialty pharmaceutical company’s stock after selling 174 shares during the quarter. Globeflex Capital L P’s holdings in Jazz Pharmaceuticals were worth $154,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Park Avenue Securities LLC increased its stake in shares of Jazz Pharmaceuticals by 2.3% in the fourth quarter. Park Avenue Securities LLC now owns 3,100 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 70 shares during the period. IFP Advisors Inc boosted its holdings in shares of Jazz Pharmaceuticals by 26.5% during the 4th quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock valued at $64,000 after buying an additional 75 shares in the last quarter. Captrust Financial Advisors boosted its stake in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock worth $577,000 after purchasing an additional 86 shares in the last quarter. Huntington National Bank boosted its stake in Jazz Pharmaceuticals by 37.9% in the 4th quarter. Huntington National Bank now owns 324 shares of the specialty pharmaceutical company’s stock worth $52,000 after purchasing an additional 89 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 90.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 215 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 102 shares during the period. Institutional investors own 89.79% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on JAZZ shares. The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $190.00 to $212.00 and gave the company a “buy” rating in a research report on Friday, March 3rd. Needham & Company LLC increased their target price on Jazz Pharmaceuticals from $205.00 to $212.00 in a research report on Thursday, May 11th. StockNews.com began coverage on Jazz Pharmaceuticals in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $204.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, March 6th. Finally, Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $207.00 to $202.00 in a research note on Thursday, May 11th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $200.75.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CFO Renee D. Gala sold 6,000 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $131.75, for a total transaction of $790,500.00. Following the completion of the sale, the chief financial officer now directly owns 35,978 shares of the company’s stock, valued at approximately $4,740,101.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Renee D. Gala sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $131.75, for a total transaction of $790,500.00. Following the completion of the transaction, the chief financial officer now directly owns 35,978 shares of the company’s stock, valued at $4,740,101.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Patricia Carr sold 1,023 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $133.22, for a total value of $136,284.06. Following the completion of the transaction, the chief accounting officer now directly owns 6,286 shares of the company’s stock, valued at $837,420.92. The disclosure for this sale can be found here. Insiders have sold 15,580 shares of company stock worth $2,127,210 in the last quarter. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Down 0.9 %

NASDAQ JAZZ traded down $1.17 during trading hours on Friday, hitting $126.38. 57,051 shares of the company were exchanged, compared to its average volume of 487,545. The company has a 50 day moving average of $140.09 and a two-hundred day moving average of $147.23. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 1.71. Jazz Pharmaceuticals plc has a 52-week low of $125.35 and a 52-week high of $163.31. The firm has a market cap of $8.09 billion, a price-to-earnings ratio of -50.22, a PEG ratio of 0.73 and a beta of 0.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last released its quarterly earnings data on Wednesday, March 1st. The specialty pharmaceutical company reported ($0.84) EPS for the quarter. Jazz Pharmaceuticals had a negative net margin of 4.18% and a positive return on equity of 24.72%. The business had revenue of $972.12 million during the quarter, compared to analysts’ expectations of $972.70 million. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 14.75 earnings per share for the current year.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.